KOFU, JAPAN--December 21, 2023--Researched by Industrial Info Resources (Sugar Land, Texas)--SK Bioscience (Seoul, South Korea) in June announced that its Phase 2 clinical trial of the 21 valence pneumococcal vaccine SKYPAC, which is being developed in collaboration with Sanofi (NASDAQ:SNY) (Paris, France), had successfully ended.
(All Fields Required)
Site-wide Scheduled Maintenance for April 12, 2025, between 9 A.M. - 9 P.M. CST. During this time, all services will be unavailable periodically throughout the scheduled maintenance window.
×Contact Us
For More Info!
